<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2020-24-5-29-36</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-1880</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Роль ожирения в поражении почекубольных схронической сердечной недостаточностью</article-title><trans-title-group xml:lang="en"><trans-title>The role of obesity in renal damage in patients with chronic heart failure</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3306-0312</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стаценко</surname><given-names>М. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Statsenko</surname><given-names>M. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Стаценко Михаил Евгеньевич, д-р мед. наук </p><p>проректор по научной работе, заведующий кафедрой внутрен­них болезней педиатрического и стоматологического факуль­тетов</p><p>400131, г. Волгоград, площадь Павших Борцов, д. 1. Тел.: (8442)38-53-57; 53-23-35</p></bio><bio xml:lang="en"><p>Prof. Mikhail E. Statsenko, MD, PhD, DmedSci </p><p>Department of Internal Medicine, Pediatric faculty/Dental faculty</p><p>Affiliations: 400131, Russia, Volgograd, 1, Pavshikh Bortsov Sq.  Phone: (8442) 38-53-57; 53-23-35</p></bio><email xlink:type="simple">mestatsenko@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5736-2235</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фабрицкая</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fabritskaya</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доц. Фабрицкая Светлана Валерьевна, канд. мед. наук </p><p>Кафедра внутренних болезней педиатрического и стоматологического факультетов</p><p>400131, г. Волгоград, площадь Павших Борцов, д. 1. Тел.: (8442)24-22-92 </p></bio><bio xml:lang="en"><p>Svetlana V. Fabritskaya, MD, PhD</p><p>Department of Internal Medicine, Pediatric faculty/Dental faculty</p><p>Affiliations: 400131, Russia, Volgograd, 1, Pavshikh Bortsov Sq.  Phone: (8442)24-22-92</p></bio><email xlink:type="simple">lanabelenkova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9351-3002</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рындина</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryndina</surname><given-names>Y. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рындина Юлия Андреевна, аспирант</p><p>Кафедра внутренних болезней педиатрического и стоматологического факультетов</p><p>400131, г. Волгоград, площадь Павших Борцов, д. 1. Тел.: (8442)24-22-92</p></bio><bio xml:lang="en"><p>Yuliya A. Rindina.</p><p>Department of Internal Medicine, Pediatric faculty/Dental faculty</p><p>Affiliations: 400131, Russia, Volgograd, 1, Pavshikh Bortsov Sq. Phone: (8442)24-22-92</p></bio><email xlink:type="simple">rindina91@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Волгоградский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>31</day><month>08</month><year>2020</year></pub-date><volume>24</volume><issue>5</issue><fpage>29</fpage><lpage>36</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Стаценко М.Е., Фабрицкая С.В., Рындина Ю.А., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Стаценко М.Е., Фабрицкая С.В., Рындина Ю.А.</copyright-holder><copyright-holder xml:lang="en">Statsenko M.E., Fabritskaya S.V., Ryndina Y.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/1880">https://journal.nephrolog.ru/jour/article/view/1880</self-uri><abstract><p>ЦЕЛЬ: изучить особенности функционального состояния почекубольныхсхронической сердечной недостаточностью (ХСН) и ожирением. ПАЦИЕНТЫ И МЕТОДЫ. 116 больных с ХСН I-III функционального класса (ФК) 45-65 лет разде­лены на три сопоставимые группы в зависимости от индекса массы тела (ИМТ). Проводили физикальное обследо­вание, оценивали функциональное состояние почек, сывороточный и уровень лептина и адипонектина, индекс инсу- линорезистентности, анализировали комбинированный риск прогрессирования хронической болезни почек (ХБП) и развития сердечно-сосудистых осложнений. РЕЗУЛЬТАТЫ. Среди пациентов с ХСН и ожирением отмечено статисти­чески значимое снижение скорости клубочковой фильтрации (СКФ) в сравнении с больными 1-й группы [61,3 (46,2; 67,1) vs 73,2 (62,1; 86,3) мл/мин/1,73 м2], достоверно чаще выявлялось клинически значимое снижение СКФ&lt;60 мл/ мин/1,73 м2 (ХБП С3а-3б), высокая (А2) и очень высокая (АЗ) альбуминурия по сравнению с пациентами с нормальной и избыточной массой тела. Концентрация лептина достоверно увеличивалась от 1-й к 3-й группе, в то время как кон­центрация адипонектина уменьшалась от 1-й к 3-й группе. Установлены статистически значимые корреляции между концентрацией лептина и СКФ (г=-0,52), АУ (г=0,36), между концентрацией адипонектина и СКФ (г=0,38), АУ (г=-0,32). Среди больных с избыточной массой тела и ожирением выявлены достоверные ассоциации между выраженностью АУ, СКФ и HOMA-IR, метаболическим индексом. ЗАКЛЮЧЕНИЕ. Установлено достоверное ухудшение функциональных параметров почеку больных с ХСН по мере нарастания массы тела, а также увеличение комбинированного риска про­грессирования ХБП и развития сердечно-сосудистых осложнений при сопоставимом ФК. Выявленные достоверные взаимосвязи отражают значительный патогенетический вклад гормональной активности висцеральной жировой тка­ни и инсулинорезистентности в развитие и прогрессирование почечнойдисфункцииубольныхсХСН и ожирением.</p></abstract><trans-abstract xml:lang="en"><p>THE AIM: to study the functional state ofthe kidneys in patientswith chronic heart failure (CHF)and obesity. PATIENTS AND METH­ODS. 116 patients with CHF l-lll functional class (FC) 45-65 years old are divided into three comparable groups depending on body mass index (BMI). A physical examination was performed, evaluated the renal function, the level of leptin and adiponectin, assessed the insulin resistance index, the combined risk of progression of chronic kidney disease (CKD), and the development of cardiovascular complications was analyzed. RESULTS. Among patients with CHF and obesity, a statistically significant decrease in glomerular filtration rate (GFR) was observed compared with patients of the 1st group (61.3 [46.2; 67.1] vs 73.2 [62.1; 86.3] ml/min / 1.73 m2), a clinically significant decrease in GFR &lt;60 ml/min /1.73 m2 (CKD C3a-3b), high (A2) and very high (A3) albu­minuria (AU) compared in patientswith normal and overweight. The leptin concentration significantly increased from the 1st to the 3rd group, while the adiponectin concentration decreased from the 1st to the 3rd group. Statistically significant correlations were established between the concentration of leptin and GFR (r = -0.52), AC (r = 0.36), between the concentration of adiponectin and GFR (r = 0.38), AC (r = -0.32). Significant associations were found among patientswith overweight and obesity between the severity of AU, GFR, and HOMA-IR, metabolic index. CONCLUSION. A significant deterioration in the functional parameters ofthe kidneys in patientswith CHF with increasing body weight, as well as an increase in the combined risk of CKD progression and the development of cardiovascular complications with comparable FC, was established. The revealed reliable relationships reflect the significant pathogenetic contribution of the hormonal activity of visceral adipose tissue and insulin resistance to the development and progression of renal dysfunction in patients with heart failure and obesity.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>экскреторная функция почек</kwd><kwd>хроническая болезнь почек</kwd><kwd>хроническая сердечная недостаточ­ность</kwd><kwd>ожирение</kwd><kwd>сердечно-сосудистый риск</kwd><kwd>лептин</kwd><kwd>адипонектин</kwd><kwd>инсулинорезистентность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>renal function</kwd><kwd>chronic kidney disease</kwd><kwd>chronic heart failure</kwd><kwd>obesity</kwd><kwd>cardiovascular risk</kwd><kwd>leptin</kwd><kwd>adiponectin</kwd><kwd>insulin resistance</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Шляхто ЕВ, Недогода СВ, Конради АО. Национальные клинические рекомендации «Диагностика, лечение, профи­лактика ожирения и ассоциированных с ним заболеваний». СПб., 2017;1-164</mixed-citation><mixed-citation xml:lang="en">Shlyakhto EV, Nedogoda SV, Konradi AO. National clinical recommendations «Diagnosis, treatment, prevention of obesity and associated diseases». St. Petersburg, 2017;1-164 (ln Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart 2017;103(23):1848-1853. doi: 10.1136/heartjnl-2016-310794</mixed-citation><mixed-citation xml:lang="en">Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart 2017;103(23):1848-1853. doi: 10.1136/heartjnl-2016-310794</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Насыбуллина AA, Булашова OB, Ослопов BH и др. Кли­ническая характеристика пациентов с сердечной недостаточ­ностью в сочетании с хронической болезнью почек. Вестник современной клинической медицины 2015;8( 1):85-89</mixed-citation><mixed-citation xml:lang="en">Nasibullina AA, Bulashova OV, Oslopov VN et al. The clinical characteristics of patients with heart failure in combination with chronic kidney diseas. The Bulletin of Contemporary Clinical Medi­cine 2015;8(Suppl. 1):85-89 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев ВС, Мухин НА, Смирнов АВ и др. Нацио­нальные рекомендации: Сердечно-сосудистый риск и хро­ническая болезнь почек: стратегии кардионефропротекции. Российский кардиологический журнал 2014;8(112):7-37. doi: 10.15829/1560-4071-2014-8-7-37</mixed-citation><mixed-citation xml:lang="en">Moiseev VS, Mukhin NA, Smirnov AVetal. Clinical guidelines. Cardiovascular risk and chronic kidney disease: cardionephropro- tection. Russian Journal of Cardiology 20t4\8( 112):7-37 (In Russ.), doi: 10.15829/1560-4071-2014-8-7-37</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Garofalo C, Borrelli S, Minutolo R et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int 2017;91(5): 1224-1235. doi: 10.1016/j.kint.2016.12.013</mixed-citation><mixed-citation xml:lang="en">Garofalo C, Borrelli S, Minutolo R et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int 2017;91(5): 1224-1235. doi: 10.1016/j.kint.2016.12.013</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Российское кардиологическое общество. Национальное общество специалистов по заболеваниям миокарда и сердеч­ной недостаточности. Общество специалистов по сердечной недостаточности. Клинические рекомендации 2019 https://scardio.ru/content/activities/2019/guide/KP_XCH_2019.pdf</mixed-citation><mixed-citation xml:lang="en">Russian Cardiology Society. National Society of Specialists in Myocardial Disease and Heart Failure. Society of Heart Failure Specialists. Clinical recommendations 2019 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнов АВ, Шилов EM, Добронравов BA и др. Нацио­нальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению 2019 http://nonr.ru/wp-content/uploads/2020/01/Clin_guidlines_CKD_24.11_final-3-3.pdf</mixed-citation><mixed-citation xml:lang="en">Smirnov AV, Shilov EM, Dobronravov VAet al. National guide­lines. Chronic kidney disease: basic principles of screening, diag­nosis, prevention and treatment approaches 2019 (In Russ.) http://nonr.ru/wp-content/uploads/2020/01/Clin_guidlines_CKD_24.11_final-3-3.pdf</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Недогода СВ, Барыкина ИН, Саласюк AC. Националь­ные клинические рекомендации по ожирению: концепция и перспективы. Вестник Волгоградского государственного медицинского университета 2017;1(61):134-140</mixed-citation><mixed-citation xml:lang="en">Nedogoda SV, Barykina IN, Salasyuk AS. National clinical recommendations for obesity: concept and perspectives. Vestnik Voigogradskogo gosudarstvennogo meditsinskogo universiteta 2017;1(61):134-140 (ln Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Amato MC. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardio- metabolic risk in a Caucasian Sicilian population. Lipids Health Dis 2011;10(183):1-8</mixed-citation><mixed-citation xml:lang="en">Amato MC. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardio- metabolic risk in a Caucasian Sicilian population. Lipids Health Dis 2011;10(183):1-8</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ройтберг ГЕ, Дорош ЖВ, Шархун ОО и др. Возможно­сти применения нового метаболического индекса при оценке инсулинорезистентности в клинической практике. Рациональ­ная Фармакотерапия в Кардиологии 2014;10(3):264-274. doi: 10.20996/1819-6446-2014-10-3-264-274</mixed-citation><mixed-citation xml:lang="en">Roytberg GE, Dorosh JV, Sharkhun OO et al. New metabolic index use potentialities in evaluation of insulin resistance in clinical practice. Rational Pharmacotherapy in Cardiology 2014; 10(3) :264- 274 (In Russ.), doi: 10.20996/1819-6446-2014-10-3-264-274</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Foster MC, Hwang SJ, Larson MG et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008;52(1):39-48. doi: 10.1053/j.ajkd.2008.03.003</mixed-citation><mixed-citation xml:lang="en">Foster MC, Hwang SJ, Larson MG et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008;52(1):39-48. doi: 10.1053/j. ajkd.2008.03.003</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Попова ИР, Торчинский HB, ДрапкинаОМ, Ивашкин ВТ. Оценка функционального состояния почеку пациентов с избы­точной массой тела и ожирением. Клиницист 2012; 6(2): 36-40. doi: 10.17650/1818-8338-2012-6-2-36-40</mixed-citation><mixed-citation xml:lang="en">Popova IR, Torchinskiy NV, DrapkinaO, Ivashkin VT Assess­ment of real function in patiens with overweight and obesity. The Clinician 2012;6(2):36-40 (In Russ.), doi: 10.17650/1818-8338­2012-6-2-36-40</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Резник ЕВ, Никитин ИГ. Кардиоренальный синдром у больных с сердечной недостаточностью как этап кардиоре­нального континуума (часть I): определение, классификация, патогенез, диагностика, эпидемиология (обзор литера­туры). Архивъ внутренней медицины 2019;9(1):5-22. doi: 10.20514/2226-6704-2019-9-1-5-22</mixed-citation><mixed-citation xml:lang="en">Reznik EV, Nikitin IG. Cardiorenal syndrome in patients with chronic heart failure as a stage of the cardiorenal continuum (part I): definition, classification, pathogenesis, diagnosis, epidemiol­ogy. The Russian Archives of Internal Medicine 2019;9 (1):5-22 (In Russ.), doi: 10.20514/2226-6704-2019-9-1-5-22</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава ЖД, Виллевальде СВ, Багманова НХ и др. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией в зависимости от наличия сахарного диабета: результаты эпидемиологического исследования ХРОНОГРАФ. Российский кардиологический журнал 2018;2(154):91-101. doi: 10.15829/1560-4071-2018­2-91-101</mixed-citation><mixed-citation xml:lang="en">Kobalava ZD, Villevalde SV, Bogmanova NK et al. The prevalence of chronic kidney disease markers in arterial hyper­tension patients and relation with diabetes: results of epidemio­logical study KHRONOGRAPH. Russian Journal of Cardiology 2018;2(154):91-101 (In Russ.), doi: 10.15829/1560-4071-2018­2-91-101</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kuol-C,Wu P-H, LinY-Hetal. The association of adiponec- tin with metabolic syndrome and clinical outcome in patients with non-diabetic chronic kidney disease. 2019 Jul 19;14(7): e0220158. doi: 10.1371/journal.pone.0220158</mixed-citation><mixed-citation xml:lang="en">Kuol-C,Wu P-H, LinY-Hetal. The association of adiponec- tin with metabolic syndrome and clinical outcome in patients with non-diabetic chronic kidney disease. 2019 Jul 19;14(7):e0220158. doi: 10.1371 /journal.pone.0220158</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma K. The link between obesity and albuminuria: adi- ponectin and podocyte dysfunction. Kidney Int 2009;76:145-148</mixed-citation><mixed-citation xml:lang="en">Sharma K. The link between obesity and albuminuria: adi- ponectin and podocyte dysfunction. Kidney Int 2009;76:145-148</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zhong Yu J, Kalantar-Zadeh K, Rhee CM. Adiponectin and Leptin in Kidney Disease Patients: Diagnosis and Treatment Endocrine Disorders in Kidney Disease, pp.277-290 January 2019:10.1007/978-3-319-97765-2_20</mixed-citation><mixed-citation xml:lang="en">Zhong Yu J, Kalantar-Zadeh K, Rhee CM. Adiponectin and Leptin in Kidney Disease Patients: Diagnosis and Treatment Endocrine Disorders in Kidney Disease, pp.277-290 January 2019:10.1007/978-3-319-97765-2_20</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol 2006; 151:175-183</mixed-citation><mixed-citation xml:lang="en">Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol 2006; 151:175-183</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ellington AA, MalikAR, KleeGGetal. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 2007;50:708-714</mixed-citation><mixed-citation xml:lang="en">Ellington AA, MalikAR, KleeGGetal. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 2007;50:708-714</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Шишкова ЮН, Миняйлова HH, Ровда ЮИ, Каракова ЛМ. Механизмы поражения почек при ожирении и метаболи­ческом синдроме (обзор литературы). Мать и дитя в Кузбассе 2018;2(73):9-15</mixed-citation><mixed-citation xml:lang="en">Shishkova UN, Minyailova NN, RovdaYul, Karakova LM. Mechanisms of kidney damage in obesity and metabolic syndrome (literature review). Mother and child in Kuzbass 2018;2(73):9-15 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Artunc F, Schleicher E, Weigert С et al. The impact of in­sulin resistance on the kidney and vasculature. Nat Rev Nephrol 2016;12(12):721-737. doi: 10.1038/nrneph.2016.145</mixed-citation><mixed-citation xml:lang="en">Artunc F, Schleicher E, Weigert С et al. The impact of in­sulin resistance on the kidney and vasculature. Nat Rev Nephrol 2016;12(12):721-737. doi: 10.1038/nrneph.2016.145</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ruster C, Wolf G. The role of the renin-angiotensin-aldos- terone system in obesity-related renal diseases. Semin Nephrol 2013;33:44-53</mixed-citation><mixed-citation xml:lang="en">Ruster C, Wolf G. The role of the renin-angiotensin-aldos- terone system in obesity-related renal diseases. Semin Nephrol 2013;33:44-53</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Noor S, Alam F, Fatima SS et al. Role of Leptin and dyslipi- demia in chronic kidney disease. PakJPharm Sci 2018;31 (3):893- 897</mixed-citation><mixed-citation xml:lang="en">Noor S, Alam F, Fatima SS et al. Role of Leptin and dyslipi- demia in chronic kidney disease. PakJPharm Sci 2018;31 (3):893- 897</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">ВялковаАА, Лебедева EH, Красиков СИ и др. Клинико­патогенетические аспекты повреждения почек при ожирении (обзор литературы). Нефрология 2014:3(18):24-33</mixed-citation><mixed-citation xml:lang="en">Vyalkova AA, Lebedeva EN, Krasikov SI et al. Clinical and pa- phogenical aspects of kidney damage in obesity (review). Nephrol­ogy (Saint-Petersburg) 2014;18(3):24-33 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Saraheimo M, ForsblomC, Thorn Letal. Serum adiponec­tin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008;31(6):1165-1169. doi: 10.2337/ dc07-2306</mixed-citation><mixed-citation xml:lang="en">Saraheimo M, ForsblomC, Thorn Letal. Serum adiponec­tin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008;31(6):1165-1169. doi: 10.2337/ dc07-2306</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Федорова ЕЮ, Кутырина ИМ. Механизмы прогресси­рования поражения почек при ожирении. Нефрология и диализ 2006;(2):3-12</mixed-citation><mixed-citation xml:lang="en">Fedorova EYu, Kutirina IM et al. Mechanisms of the kidney damage in case of obesity (review). Nephrology and dialysis 2006;(2):3-12(lnRuss.)</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ahima RS. Linking adiponectin to proteinuria. JCI 2008;118(2):1619-1622</mixed-citation><mixed-citation xml:lang="en">Ahima RS. Linking adiponectin to proteinuria. JCI 2008;118(2):1619-1622</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">RishengX Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab 2013; 2(3): 133-141</mixed-citation><mixed-citation xml:lang="en">RishengX Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab 2013; 2(3): 133-141</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Stenvinkel P. Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. Journal of Renal Nutrition 2011;21(1):82-86</mixed-citation><mixed-citation xml:lang="en">Stenvinkel P. Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. Journal of Renal Nutrition 2011;21(1):82-86</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Jeon WS, Park JW, Lee N et al. Urinary adiponectin con­centration is positively associated with micro- and macrovascular complications. Cardiovasc Diabet 2013; 12:137</mixed-citation><mixed-citation xml:lang="en">Jeon WS, Park JW, Lee N et al. Urinary adiponectin con­centration is positively associated with micro- and macrovascular complications. Cardiovasc Diabet 2013; 12:137</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Бабенко АЮ, Байрашева BK. Диабетическая нефропа­тия: зависит ли ренопротекция от выбора сахароснижающей терапии? Медицинский совет2015:7:32-43. doi: 10.21518/2079-701Х-2015-7-32-43</mixed-citation><mixed-citation xml:lang="en">Babenko АХ Bayrasheva VK. Diabetic nephropathy. Is renoprotection determined by the choice of hypoglycemic therapy? Meditsinskiy sovet 2015;(7):32-43 (In Russ.), doi: 10.21518/2079-701X-2015-7-32-43</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Вялкова AA, Лебедева EH, Афонина CH и др. Заболе­вания почек и ожирение: молекулярные взаимосвязи и новые подходы к диагностике (обзор литературы). Нефрология 2017;21(3):25-38. doi: 10.24884/1561-6274-2017-3-25-38</mixed-citation><mixed-citation xml:lang="en">Vyalkova AA, Lebedeva EN, Afonina SN et al. Kidney dis­eases and obesity: molecular relationship and new approaches to diagnosis (literature review). Nephrology (Saint-Petersburg) 2017;21(3):25-38 (In Russ.), doi: 10.24884/1561-6274-2017-3­25-38</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
